CHICAGO, Illinois, USA, June 2, 2026
AstraZeneca has announced compelling new results from its pivotal Phase III SERENA-6 trial, demonstrating that camizestrant combined with a CDK4/6 inhibitor significantly delays disease progression and improves long-term outcomes in patients with HR-positive, HER2-negative advanced breast cancer carrying emergent ESR1 mutations. Presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, the findings reinforce the potential of an innovative ctDNA-guided treatment strategy that allows physicians to switch therapies before clinical progression occurs, potentially redefining first-line treatment standards for this common form of advanced breast cancer.
Significant Progression-Free Survival Benefit Demonstrated
The updated SERENA-6 analysis showed that patients who switched from standard endocrine therapy to a camizestrant plus CDK4/6 inhibitor combination experienced a 55% reduction in the risk of disease progression or death compared with those who continued receiving an aromatase inhibitor plus a CDK4/6 inhibitor. Median progression-free survival (PFS) reached 16.8 months versus 9.2 months, representing a clinically meaningful improvement of 7.6 months.
Furthermore, the treatment demonstrated durability beyond first progression, reducing the risk of second disease progression or death by 37% and extending median second progression-free survival (PFS2) to 25.7 months compared with 19.1 months for standard therapy. These outcomes suggest that earlier intervention based on molecular monitoring may offer patients sustained disease control and delay the need for more aggressive treatment options.
ctDNA Clearance Highlights Strong Anti-Tumor Activity
Advertisement
One of the most striking findings from SERENA-6 involved the impact of camizestrant on circulating tumor DNA (ctDNA), an increasingly important biomarker of treatment response. Patients receiving the camizestrant combination achieved a remarkable 99% median reduction in total ctDNA levels within eight weeks, while those remaining on standard treatment experienced a 64% increase in ctDNA. Additionally, 51% of patients achieved complete ctDNA clearance, compared with only 1.9% in the control arm.
Early ctDNA clearance has been associated with improved long-term outcomes and overall survival in several cancer studies, making these results particularly significant. Researchers believe the findings provide robust biological evidence that switching treatment upon detection of ESR1 mutations can effectively suppress tumor activity before visible disease progression occurs.
Potential to Transform First-Line Treatment Strategy
The SERENA-6 trial is the first global registrational Phase III study to utilize a ctDNA-guided treatment-switching approach in advanced breast cancer. The trial enrolled 315 patients whose tumors developed ESR1 mutations while receiving first-line endocrine therapy and a CDK4/6 inhibitor. Instead of waiting for radiographic disease progression, investigators used routine blood-based ctDNA testing to identify emerging resistance and initiate an early therapeutic switch. Beyond progression-free survival improvements, camizestrant also delayed the need for chemotherapy or antibody-drug conjugates, extending chemotherapy/ADC-free survival to 22.6 months compared with 18.7 months. The treatment additionally helped maintain patient-reported quality of life and demonstrated a safety profile consistent with previously reported studies, with no new safety concerns identified.
The positive results further strengthen AstraZeneca’s growing oncology portfolio and support regulatory reviews currently underway in the United States, Japan, and other global markets. With approvals already secured in Saudi Arabia and the United Arab Emirates and a recent positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use, camizestrant is emerging as a potentially transformative therapy for patients with hormone receptor-positive advanced breast cancer who develop endocrine resistance through ESR1 mutations. As precision medicine continues to evolve, the SERENA-6 findings may mark a major shift toward earlier molecular intervention and more personalized treatment strategies in breast cancer care.
Source: AstraZeneca press release
